All Updates

All Updates

icon
Filter
M&A
Certara acquires Chemaxon for undisclosed amount to increase predictive abilities in drug discovery
AI Drug Discovery
Jul 9, 2024
This week:
Partnerships
Qualcomm and Google partner to develop AI-driven automotive solutions
Auto Tech
Yesterday
Product updates
Meta AI releases LayerSkip to accelerate inference in LLMs
Generative AI Infrastructure
Yesterday
Funding
Freeform secures funding from NVIDIA's NVentures
Additive Manufacturing
Oct 22, 2024
Product updates
Flexxbotics announces compatibility with LMI Technologies for quality inspection
Smart Factory
Oct 22, 2024
Funding
Oxla raises USD 11 million in seed funding to drive commercialization
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Cohesity enhances Gaia, its AI assistant, with visual data exploration and expanded data sources
Data Infrastructure & Analytics
Oct 22, 2024
Product updates
Finzly launches FedNow service through BankOS platform in AWS marketplace
FinTech Infrastructure
Oct 22, 2024
Product updates
Runway launches Act-One for AI facial expression motion capture
Generative AI Applications
Oct 22, 2024
Product updates
Ideogram launches Canvas for image manipulation and generation
Generative AI Applications
Oct 22, 2024
Partnerships
UiPath partners with Inflection AI to integrate AI solutions for enterprises
Generative AI Applications
Oct 22, 2024
AI Drug Discovery

AI Drug Discovery

Jul 9, 2024

Certara acquires Chemaxon for undisclosed amount to increase predictive abilities in drug discovery

M&A

  • Pennsylvania-based pharmaceutical company Certara has entered a definitive agreement to acquire cheminformatics software provider Chemaxon for an undisclosed sum.

  • Post-acquisition, Certara plans to combine its technology with Chemaxon's to enhance prediction and analytical capabilities in drug discovery. The company aims to offer a comprehensive data and predictive analytics platform to improve decision-making from discovery through commercialization in the life sciences sector.

  • Certara specializes in providing software products and technology-enabled services, including AI-powered solutions to the pharmaceutical sector. The company's focus is on model-informed drug development, offering solutions that predict pharmacokinetics and pharmacodynamics through software services such as Simcyp Simulator, which predicts drug behavior within the human body, and Phoenix WinNonlin IVIV for in vitro-in vivo correlation (IVIVC) studies.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.